Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Label-Free Raman Approaches for Patient-Specific Biochemical Tumor Mapping to Monitor Personalized Anticancer Resistance Simulation

Project description

Imaging of treatment resistance in cancer

Resistance to anticancer therapies remains a significant issue, especially in aggressive malignancies such as head and neck squamous cell carcinoma (HNSCC). There are no rapid and reliable methods for detecting therapy resistance before it leads to treatment failure. With the support of the Marie Skłodowska-Curie Actions programme, the RAMPART project will develop a label-free imaging platform based on Raman and multimodal spectroscopy to identify early biomarkers of resistance in ex vivo tumour sections. By mapping biochemical changes in the tumour microenvironment after therapy, researchers hope to advance precision oncology and improve the outcome for patients with HNSCC.

Objective

RAMPART aims to address the significant clinical challenge of tumor resistance to anticancer therapies, a key factor contributing to
treatment failure and decreased patient survival, particularly in Head and Neck Squamous Cell Carcinoma (HNSCC). The project’s
primary objective is to develop a label-free, nondestructive and rapid methodology using Raman and multimodal imaging to identify
biomarkers of tumor resistance, by monitoring the biochemical responses of ex vivo patient-derived tumor slices to both immunotherapy
and radiotherapy.
To do so, RAMPART will employ cutting-edge Raman spectroscopy, including both spontaneous (SR) and a multimodal microscope
(SRS-TPEF-SHG), to perform high-resolution biomolecular mapping and imaging of patient-derived tumor samples. This approach
allows for precise detection of biomolecular changes within the tumor microenvironment (TME), offering a comprehensive
understanding of the factors driving therapy resistance. The project will be conducted at Politecnico di Milano (main host), and two
secondments at Jena University Hospital (UKJ) and Johns Hopkins University (JHU), where I will prepare patient-derived
HNSCC slices.
The relevance of RAMPART lies in its potential to significantly enhance clinical decision-making in HNSCC oncology,
advancing the state-of-the-art in tumor evaluation, with label-free and nondestructive approaches for biomolecular tumor imaging.
By establishing a protocol for the early detection of resistance biomarkers, the project will enable rapid, personalized treatment
strategies tailored to individual patients, driving to decision-making time of 5-7 days. Additionally, the insights gained into tumor
heterogeneity and the TME will contribute to a more profound understanding of their roles in treatment outcomes. The project’s
findings are expected to potentially impact on the field of precision medicine, ultimately improving survival rates and quality
of life for patients with HNSCC.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2024-PF-01

See all projects funded under this call

Coordinator

POLITECNICO DI MILANO
Net EU contribution
€ 209 483,28
Address
PIAZZA LEONARDO DA VINCI 32
20133 Milano
Italy
Region
Nord-Ovest Lombardia Milano
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Partners (2)